tradingkey.logo
搜尋

Precipio Inc

PRPO
添加自選
25.260USD
+0.330+1.32%
收盤 07/02, 13:00美東報價延遲15分鐘
45.06M總市值
虧損本益比TTM

Precipio Inc

25.260
+0.330+1.32%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.32%

5天

+8.37%

1月

+8.13%

6月

+6.05%

今年開始到現在

+9.92%

1年

+109.63%

關鍵數據
25.293今開
25.365最高
6.89K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.39%換手率
24.930昨收
22.760最低
72.66K成交額
虧損本益比靜
3.18市淨率
0.00%股息率 TTM
-4.78%ROA
33.63052週最高
0.61量比
-4.29M淨利潤
1.78M總股本
-0.4471每股盈餘TTM
1.33Beta
-7.13%ROE
9.30052週最低
10.45%振幅
40.60%毛利率
45.06M總市值
1.53回報/風險
4.39%風險率

TradingKey Precipio Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Precipio Inc當前公司基本面數據相對穩定,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名150/204位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現較強,技術面評分較高,但較強的走勢未獲得基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Precipio Inc評分

相關信息

行業排名
150 / 204
全市場排名
431 / 4565
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Precipio Inc亮點

亮點風險
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
業績高增長
公司營業收入穩步增長,連續3年增長58.25%
業績增長期
公司處於發展階段,最新年度總收入24.05M美元
估值低估
公司最新PE估值-56.49,處於3年歷史低位
機構減倉
最新機構持股341.74K股,環比減少7.77%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間

Precipio Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Precipio Inc簡介

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
公司代碼PRPO
公司Precipio Inc
CEODanieli (Ilan S)
網址https://www.precipiodx.com/

常見問題

Precipio Inc(PRPO)的當前股價是多少?

Precipio Inc(PRPO)的當前股價是 25.26。

Precipio Inc 的股票代碼是什麼?

Precipio Inc的股票代碼是PRPO。

Precipio Inc股票的52週最高點是多少?

Precipio Inc股票的52週最高點是33.63。

Precipio Inc股票的52週最低點是多少?

Precipio Inc股票的52週最低點是9.30。

Precipio Inc的市值是多少?

Precipio Inc的市值是45.06M。

Precipio Inc(PRPO)股票的每股收益(EPS TTM)是多少

Precipio Inc(PRPO)股票的每股收益(EPS TTM)是-0.23。